

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-10. (CANCELED)

11. (CURRENTLY AMENDED) A physiological assessment method comprising determining a level of at least one of resistin-like molecule α (RELM α) or resistin-like molecule β (RELM β) in a pulmonary tissue selected from the group consisting of lung fluid, lung biopsy, sputum, mucus, nasal washings, bronchoalveolar fluid, respiratory tract tissue, respiratory tract fluid, and combinations thereof, of a patient to assess a patient clinical status parameter indicative of a pulmonary pulmonary disease, ~~the parameter selected from the group consisting of clinical status, phenotype, genotype, drug response, prognosis, single nucleotide polymorphisms, and combinations thereof~~ wherein an increased level of at least one RELM α or RELM β indicates a pulmonary inflammatory process or chronic repair process in the patient.

12. (CURRENTLY AMENDED) The method of claim 11 wherein RELM α or RELM β is determined in ~~at least one of lung fluid, lung biopsy, sputum, mucus, nasal washings, bronchoalveolar fluid, respiratory tract tissue, respiratory tract fluid, blood, and combinations thereof.~~

13. (ORIGINAL) The method of claim 11 wherein at least one of RELM α DNA, RELM β DNA, RELM α mRNA, RELM β mRNA, RELM α protein, or RELM β protein is determined.

14. (CANCELED)

15. (ORIGINAL) The method of claim 11 wherein at least one of RELM α or RELM β is determined qualitatively, quantitatively, or functionally.

16-32. (CANCELED)